Clinical Trials

Status
Published

Recently Activated

SHOW MORE
Open
SWOG Clinical Trial Number
CTSU/A081801

Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO

Research Committee(s)
Lung Cancer
Activated
06-23-2020
ClinicalTrials.gov Registry Number
NCT04267848
Open
Phase
Accrual
0%
SWOG Clinical Trial Number
S1933

A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status

Status Notes
This study is open to accrual effective June 15, 2020 at 12:00 p.m. Pacific.
Research Committee(s)
Lung Cancer
Activated
06-15-2020
ClinicalTrials.gov Registry Number
NCT04310020
Open
Phase
II
Accrual
0%
SWOG Clinical Trial Number
S1929

Phase II Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (SCLC)

Status Notes
S1929 will open to accrual June 15, 2020, effective 12:00 pm PST.
Research Committee(s)
Lung Cancer
Activated
06-15-2020
ClinicalTrials.gov Registry Number
04334941
Open
Accrual
0%
SWOG Clinical Trial Number
S1823

A Prospective Observational Cohort Study to Assess miRNA371 for Outcome Prediction in Patients with Early Stage Germ Cell Tumors

Status Notes
The study is open for registration effective 6/1/20.
Research Committee(s)
Prevention & Epidemiology
Genitourinary Cancer
Activated
06-01-2020
Open
Phase
III
Accrual
0%
SWOG Clinical Trial Number
S1914

A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC

Status Notes
This study is open to accrual effective March 25, 2020.
Research Committee(s)
Lung Cancer
Activated
03-25-2020
ClinicalTrials.gov Registry Number
04214262
Open
Phase
II
Accrual
2%
SWOG Clinical Trial Number
S1900B

A PHASE II STUDY OF LOXO-292 IN PATIENTS WITH RET FUSION-POSITIVE STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER (LUNG-MAP SUB-STUDY)

Status Notes
S1900B will open to accrual February 10, 2020, effective 12:00 pm PST.

This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
Lung Cancer
Activated
02-10-2020